PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 90 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2022. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $395 | -99.2% | 150 | -99.1% | 0.00% | – |
| Q2 2023 | $51,935 | +4.6% | 16,214 | -4.3% | 0.00% | – |
| Q1 2023 | $49,666 | -32.9% | 16,941 | -2.8% | 0.00% | – |
| Q4 2022 | $74,000 | +76.2% | 17,430 | -0.3% | 0.00% | – |
| Q3 2022 | $42,000 | 0.0% | 17,482 | +16.7% | 0.00% | – |
| Q2 2022 | $42,000 | +27.3% | 14,980 | -1.8% | 0.00% | – |
| Q1 2022 | $33,000 | -32.7% | 15,260 | -2.0% | 0.00% | – |
| Q4 2021 | $49,000 | -75.0% | 15,571 | -46.7% | 0.00% | – |
| Q3 2021 | $196,000 | +46.3% | 29,219 | +100.4% | 0.00% | – |
| Q2 2021 | $134,000 | +5.5% | 14,577 | +11.6% | 0.00% | – |
| Q1 2021 | $127,000 | +2.4% | 13,060 | +7.6% | 0.00% | – |
| Q4 2020 | $124,000 | -15.6% | 12,140 | -16.3% | 0.00% | – |
| Q3 2020 | $147,000 | +36.1% | 14,510 | +40.1% | 0.00% | – |
| Q2 2020 | $108,000 | +35.0% | 10,355 | +8.5% | 0.00% | – |
| Q1 2020 | $80,000 | – | 9,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 2,536,156 | $21,405,000 | 2.24% |
| Palo Alto Investors LP | 1,396,163 | $11,784,000 | 0.99% |
| Camber Capital Management LP | 1,950,000 | $16,458,000 | 0.98% |
| TANG CAPITAL MANAGEMENT LLC | 800,000 | $6,752,000 | 0.95% |
| Capital Impact Advisors, LLC | 147,303 | $1,243,000 | 0.52% |
| Sofinnova Investments, Inc. | 638,026 | $5,385,000 | 0.50% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 963,212 | $8,130,000 | 0.26% |
| RICE HALL JAMES & ASSOCIATES, LLC | 466,482 | $3,937,000 | 0.22% |
| PDT Partners, LLC | 204,238 | $1,724,000 | 0.14% |
| Eversept Partners, LP | 58,251 | $491,638 | 0.12% |